Aclaris Therapeutics, Inc. (ACRS)
NASDAQ: ACRS · Real-Time Price · USD
2.240
-0.070 (-3.03%)
Feb 21, 2025, 4:00 PM EST - Market closed
Aclaris Therapeutics Revenue
Aclaris Therapeutics had revenue of $4.35M in the quarter ending September 30, 2024, a decrease of -53.18%. This brings the company's revenue in the last twelve months to $27.08M, up 26.35% year-over-year. In the year 2023, Aclaris Therapeutics had annual revenue of $31.25M with 5.03% growth.
Revenue (ttm)
$27.08M
Revenue Growth
+26.35%
P/S Ratio
5.89
Revenue / Employee
$297,571
Employees
91
Market Cap
239.72M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 31.25M | 1.50M | 5.03% |
Dec 31, 2022 | 29.75M | 22.99M | 340.05% |
Dec 31, 2021 | 6.76M | 279.00K | 4.30% |
Dec 31, 2020 | 6.48M | 2.26M | 53.35% |
Dec 31, 2019 | 4.23M | -1.92M | -31.28% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
ACRS News
- 10 days ago - New Publication Highlights Unique Properties of ATI-2138, a Potent and Selective Inhibitor of ITK and JAK3 - GlobeNewsWire
- 22 days ago - Aclaris Therapeutics Announces Formation of New Scientific Advisory Board - GlobeNewsWire
- 6 weeks ago - Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewsWire
- 2 months ago - Aclaris Stock Rises As Analyst Projects Billions In Sales For New Therapy - Benzinga
- 3 months ago - Aclaris Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference - GlobeNewsWire
- 3 months ago - Aclaris Stock Soars As Analysts See Fresh Momentum After Strategic Review And Encouraging Promising Pipeline Developments - Benzinga
- 3 months ago - Biosion Announces Exclusive, Global License Agreement with Aclaris Therapeutics on two potential First-in-Class and Best-in-Class Immunology Assets - PRNewsWire
- 3 months ago - Aclaris Therapeutics Announces Exclusive, Global License Agreement with Biosion, Inc., adding Potential Best-in-Class Biologics Assets to Pipeline - GlobeNewsWire